This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Wed, 02/07/2024 - 18:05 February 7, 2024 — The Consumer Technology Association ( CTA ) and the American College of Cardiology ( ACC ) are announcing the release of their second industry framework for the use of consumer cardiovasculartechnology solutions in the screening and diagnosis for cardiovascular conditions.
Getty Images milla1cf Mon, 04/01/2024 - 08:21 April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health and other institutions conclude that new technology could soon help doctors slash that number. “We What is Valvular Heart Disease?
Getty Images milla1cf Fri, 06/28/2024 - 08:10 June 27, 2024 — Cardiovasculardisease is the leading cause of death for women, and gaps in care and access persist between women and men. Addressing those gaps could lead to an increase of at least 1.6 million years of quality life and boost the U.S.
Early detection and intervention are essential in addressing cardiovasculardiseases, and Eko is dedicated to providing accessible and scalable technologies that empower healthcare providers while improving patient care globally." Ekos algorithm was partially funded through a $2.7
mtaschetta-millane Thu, 07/25/2024 - 08:55 July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. “We
milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. million people in the United States by 2050 and 17.9 million in Europe by 2060.
This thematic issue aims to gather innovative research on the use of AI in the diagnosis, treatment, and monitoring of cardiovasculardiseases, fostering advancements in precision medicine and healthcare efficiency.
milla1cf Wed, 01/03/2024 - 12:09 January 3, 2024 — iRhythm Technologies, Inc. , The EU MDR is arguably one of the most stringent regulatory frameworks for product approvals globally that ensures medical devices meet the rigorous standards for healthcare technologies,” said Quentin Blackford, iRhythm President and Chief Executive Officer.
v As cardiovasculardisease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.
The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians. Medis Medical Imaging has been developing innovative post-processing software for the quantification of cardiovascular images for thirty-five years.
Positron joins forces with the coalitions founding members, Bracco Diagnostics , CDL Nuclear Technologies and Siemens Healthcare who have come together to promote federal policies that advance health outcomes for patients with cardiovasculardisease and improve the availability of cardiac PET diagnostics throughout the United States.
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. With this investment, we look forward to helping Cleerly expand its reach and impact, bringing this potentially life-saving innovation to more patients and health systems nationally.
Christian Tesche (Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina and Department of Cardiology, Munich University Clinic, Ludwig-Maximilian-University).
This news comes after the Innovation Value Institute ( IVI ) at Maynooth University in the Republic of Ireland selected Seismofit as one of five top digital health solutions helping to drive a radical transformation in healthcare, according to a written statement released by the company about the presentation.
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovasculardisease, one of the leading causes of death globally.
The establishment of Cardiovascular Imaging Research & Core Labs marks a pivotal leap in medical landscape, promising groundbreaking advancements and fostering innovation in cardiovascular health. This standardization is crucial in establishing reliable benchmarks for assessing treatment efficacy and innovation.
The establishment of Cardiovascular Imaging Research & Core Labs marks a pivotal leap in medical landscape, promising groundbreaking advancements and fostering innovation in cardiovascular health. This standardization is crucial in establishing reliable benchmarks for assessing treatment efficacy and innovation.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).
He completed his postgraduate training in cardiovasculardisease and nuclear cardiology at Emory School of Medicine and is board certified in internal medicine and cardiovasculardisease. I look forward to supporting new innovations to help shape the future of this great organization and the health of all people.” “As
Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings. Of these, approximately 30 are AI-enabled ultrasound innovations.
Cardiovasculardiseases (CVDs) remain the leading cause of death and disability worldwide. Digital health technologies are important public health interventions for addressing the burden of cardiovasculardisease. Journal of the American Heart Association, Volume 13, Issue 2 , January 16, 2024.
The first procedures, performed by leading physicians Saibal Kar , MD, FACC, FSCAI, (Program Director, CardiovascularDisease Fellowship, Los Robles Health System , California, HCA Healthcare National Physician Director, Interventional Cardiology) and Devi Nair , MD, FACC, FHRS, (Director, Cardiac Electrophysiology Division, St.
He added, “Adding Story Health to our ecosystem both allows providers to exceed their care quality goals and ensures patients aren’t waiting to receive ongoing care, especially between visits when they may have higher disease burden or complications that can lead to expensive emergency department visits.
Cardiovasculardisease (CVD) remains the leading cause of death in the U.S. By enabling the decisive shift from a reactive to a proactive cardiology model, this technology doesnt just improve patient outcomes it is also helping keep cardiovascular care sustainable and affordable. That future isnt decades away.
This advanced imaging technology allows me and my fellow clinicians to perform complex cardiology interventions with a high level of precision and exceptional image quality,” said Sean Mazer , M.D., According to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. It’s an honor to have the U.S.’s
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 1 To date, interventional treatment of coronary artery disease with drug-eluting stents has been able to establish flow angiographically. of the U.S. population.
As this practice grows, the study highlights the critical need to monitor the effects of private equity acquisitions on quality of care and outcomes for patients with cardiovasculardisease, as well as procedural utilization.
Getty Images milla1cf Tue, 12/12/2023 - 09:04 December 12, 2023 — The American Society of Echocardiography (ASE) and the ASE Foundation have awarded grant funding totaling $75,000 for three innovativecardiovascular ultrasound research projects led by early career investigators. Three recipients were each awarded a $25,000 grant.
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovasculardisease, and chronic kidney disease.
The introduction of Butterfly iQ3 includes a focus on higher precision capabilities for cardiovascular point-of-care ultrasound applications to inform complex decisions. said Andrei Stoica , PhD, Chief Technology Officer, Butterfly Network. milla1cf Tue, 02/13/2024 - 12:11 February 13, 2024 — Butterfly Network, Inc. ,
This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November. This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
FAHA, a professor of medicine in cardiovascular medicine at S tanford University School of Medicine and associate chief of staff for precision health at the VA Palo Alto Health Care System in Palo Alto, California. We will use modern technologies to explore the great number of chemicals in the food supply. Tsao , Ph.D.,
Harnessing Collaborative Innovation to Combat Cardiometabolic Risk Building on the foundation in Part 1 , explore real-world examples of how creative partnerships transform cardiorenal metabolic risk management. It further exemplifies the patient education and empowerment strategies.
Impacting 25 million people globally [1], deep venous disease results from venous thromboembolism, a condition that occurs when a blood clot forms in the vein [2]. It is the third most common cardiovasculardisease [2]. Deep venous anatomy and obstructions can present a multitude of complexities and mechanical challenges.
This leap in early detection marks both a significant medical innovation and a new era in the detection of cardiovasculardisease. Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations, and hopefully help address care in underserved areas.” In the U.S.,
Not only does it validate the potential of our controllably-expandable polymer conduit, but it also means the world to patients seeking options for a number of cardiovasculardiseases and conditions,” said Doug Bernstein , CEO, PECA Labs.
Improved patient safety with reduced radiation and contrast load Enhancing patient safety is a pivotal aspect of advanced cardiac imaging technology. By employing advanced scanning technology, healthcare providers can ensure patients undergo diagnostic procedures with minimized risks.
Among numerous other disorders, patients suffering from cardiovasculardiseases have the largest mortality rate. Where developing countries have somehow managed to provide treatment for their citizens suffering from cardiovasculardiseases. The surge for patients requiring cardiovascular care is enormous.
Here, we will delve into the fascinating evolution of ECG technology, exploring its origins, key milestones, and modern applications. His innovation marked a turning point in cardiac history and earned him the Nobel Prize in Physiology or Medicine in 1924. Today, it plays a vital role in various medical fields and healthcare settings.
HeartRisk combines insights from HIPAA-compliant anonymized and aggregated clinical cardiovascular data obtained through Cardio Diagnostics’ Epi+Gen CHD and PrecisionCHD clinical tests, with industry and geographic data to enable real-time population-level cardiovasculardisease (CVD) risk insights.
In the ever-evolving landscape of medical diagnostics, early disease detection stands as a critical frontier, offering the potential to save countless lives and improve patient outcomes. At the forefront of this quest lie the remarkable advancements in imaging technology, ushering in a new era of precision and insight.
In the ever-evolving landscape of medical diagnostics, early disease detection stands as a critical frontier, offering the potential to save countless lives and improve patient outcomes. At the forefront of this quest lie the remarkable advancements in imaging technology, ushering in a new era of precision and insight.
This technology represents a critical advancement in early cardiac risk stratification, offering the potential for more targeted interventions through the simple addition of a single-lead ECG," said Dr. Patrik Bächtiger, one of the co-leads of this research at Imperial. Nicholas S. Peters, Director of the Health Impact Lab at Imperial.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content